We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down
Read MoreHide Full Article
Iterum Therapeutics plc (ITRM - Free Report) recently announced updates from the meeting of the FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) that discussed its new drug application (NDA) for oral sulopenem for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women.
The FDA held the AMDAC meeting on Sept. 9, to discuss the overall benefits and risks of oral sulopenem in treating uUTIs in women aged more than 18 years and important factors for medical providers to know to ensure the proper use of sulopenem.
The FDA did not urge the AMDAC to vote on any matter.
Per some market reports, sulopenem's off-label use for treating uUTIs could be attached to a degree of high risk.
There are chances that sulopenem will be approved with certain limitations. In such a scenario, a post-marketing study would be imperative to confirm sulopenem’s proper use and label.
This might have hurt investors' sentiments and resulted in the stock going down 12% on Sept. 10 following the announcement of the news.
Shares of Iterum have plunged 51.8% so far this year compared with the industry’s decrease of 0.8%.
Image Source: Zacks Investment Research
Updates on ITRM’s NDA for Sulopenem
Iterum shared scientific evidence with the AMDAC, including data from two phase III studies, REASSURE and SURE-1, which evaluated sulopenem for the treatment of UTIs.
Per management, AMDAC acknowledged oral sulopenem as an important treatment option for patients with uUTI. It also agreed that physicians' appropriate use of oral sulopenem is critical to limiting antimicrobial resistance.
The FDA usually considers the AMDAC’s advice, but it is certainly not bound by the committee’s recommendations.
A decision from the FDA on whether or not to approve oral sulopenem as a treatment for uUTIs is due on Oct. 25, 2024.
If approved, sulopenem would become the first oral penem to be approved in the United States.
Earlier Setback Faced by ITRM
Sulopenem is an antibiotic developed to treat urinary tract and intra-abdominal infections.
We remind investors that in 2021, Iterum received a complete response letter (CRL) from the FDA against its initial NDA for oral sulopenem for the uUTIs indication. Per the CRL, the NDA could not be approved in its present form and additional data was required to support the approval of oral sulopenem for the treatment of adult women with uUTIs.
The FDA recommended Iterum to conduct an additional clinical study of the candidate, potentially using a different comparator drug.
The company resubmitted the oral sulopenem NDA for the uUTIs indication based on positive top-line results from the pivotal REASSURE study, which was announced in January 2024.
Subsequently, in June 2024, the FDA notified the company that the NDA for oral sulopenem would be discussed in the Advisory Committee meeting.
In the past 60 days, estimates for Illumina’s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 10.8%.
ILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech’s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 49.2%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 24.9%.
FULC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
ITRM Posts Updates From FDA Advisory Meeting for UTI Drug, Stock Down
Iterum Therapeutics plc (ITRM - Free Report) recently announced updates from the meeting of the FDA’s Antimicrobial Drugs Advisory Committee (AMDAC) that discussed its new drug application (NDA) for oral sulopenem for the treatment of uncomplicated urinary tract infections (uUTIs) in adult women.
The FDA held the AMDAC meeting on Sept. 9, to discuss the overall benefits and risks of oral sulopenem in treating uUTIs in women aged more than 18 years and important factors for medical providers to know to ensure the proper use of sulopenem.
The FDA did not urge the AMDAC to vote on any matter.
Per some market reports, sulopenem's off-label use for treating uUTIs could be attached to a degree of high risk.
There are chances that sulopenem will be approved with certain limitations. In such a scenario, a post-marketing study would be imperative to confirm sulopenem’s proper use and label.
This might have hurt investors' sentiments and resulted in the stock going down 12% on Sept. 10 following the announcement of the news.
Shares of Iterum have plunged 51.8% so far this year compared with the industry’s decrease of 0.8%.
Image Source: Zacks Investment Research
Updates on ITRM’s NDA for Sulopenem
Iterum shared scientific evidence with the AMDAC, including data from two phase III studies, REASSURE and SURE-1, which evaluated sulopenem for the treatment of UTIs.
Per management, AMDAC acknowledged oral sulopenem as an important treatment option for patients with uUTI. It also agreed that physicians' appropriate use of oral sulopenem is critical to limiting antimicrobial resistance.
The FDA usually considers the AMDAC’s advice, but it is certainly not bound by the committee’s recommendations.
A decision from the FDA on whether or not to approve oral sulopenem as a treatment for uUTIs is due on Oct. 25, 2024.
If approved, sulopenem would become the first oral penem to be approved in the United States.
Earlier Setback Faced by ITRM
Sulopenem is an antibiotic developed to treat urinary tract and intra-abdominal infections.
We remind investors that in 2021, Iterum received a complete response letter (CRL) from the FDA against its initial NDA for oral sulopenem for the uUTIs indication. Per the CRL, the NDA could not be approved in its present form and additional data was required to support the approval of oral sulopenem for the treatment of adult women with uUTIs.
The FDA recommended Iterum to conduct an additional clinical study of the candidate, potentially using a different comparator drug.
The company resubmitted the oral sulopenem NDA for the uUTIs indication based on positive top-line results from the pivotal REASSURE study, which was announced in January 2024.
Subsequently, in June 2024, the FDA notified the company that the NDA for oral sulopenem would be discussed in the Advisory Committee meeting.
Zacks Rank & Other Stocks to Consider
Iterum currently carries a Zacks Rank #2 (Buy).
Some other top-ranked stocks in the biotech sector are Illumina, Inc. (ILMN - Free Report) , Krystal Biotech, Inc. (KRYS - Free Report) and Fulcrum Therapeutics, Inc. (FULC - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for Illumina’s 2024 earnings per share have moved up from $1.18 to $3.62. Earnings per share estimates for 2025 have improved from $2.93 to $4.50. Year to date, shares of ILMN have lost 10.8%.
ILMN’s earnings beat estimates in each of the trailing four quarters, the average surprise being 463.46%.
In the past 60 days, estimates for Krystal Biotech’s 2024 earnings per share have increased from $1.98 to $2.38. Earnings per share estimates for 2025 have improved from $4.33 to $7.31. Year to date, shares of KRYS have risen 49.2%.
KRYS’ earnings beat estimates in three of the trailing four quarters while missing on the remaining occasion, the average surprise being 45.95%.
In the past 60 days, estimates for Fulcrum Therapeutics’ 2024 loss per share have narrowed from $1.24 to 48 cents. Loss per share estimates for 2025 have narrowed from $1.71 to $1.51. Year to date, shares of FULC have jumped 24.9%.
FULC’s earnings beat estimates in each of the trailing four quarters, the average surprise being 393.18%.